COMMUNIQUÉS West-GlobeNewswire

Imprivata Patient Access Under Construction in Epic Toolbox for Identity Verification in MyChart
14/08/2025
Integration will streamline and strengthen patient identification at all points of care, which improves PHI security, reduces duplicate medical records, and minimizes costs of denied or fraudulent claims WALTHAM, Mass [...]
Vaso Corporation Announces Financial Results for Second Quarter of 2025
14/08/2025
PLAINVIEW, N.Y., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and healthcare IT services, professional sales [...]
Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock
14/08/2025
Commack, NY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Scienture Holdings, Inc. (Nasdaq: SCNX) (“Scienture” or the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing [...]
Trinity Biotech Receives Regulatory Approval to Begin FDA-Cleared PreClara™ Preeclampsia Testing Service
14/08/2025
New York State Department of Health (NYSDOH) clinical laboratory permit facilitates Q3 2025 launch of the FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for hypertensive disorders of pregnancy DUBLIN, Aug. 14 [...]
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease
14/08/2025
Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week period Primary objective is to [...]
Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025
14/08/2025
CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second [...]
GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
14/08/2025
Live video webcast on Wednesday, August 20 th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative [...]
Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
14/08/2025
Live video webcast on Tuesday, August 19th at 2:20 PM ET SOUTH SAN FRANCISCO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company [...]
Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
14/08/2025
Live video webcast on Tuesday, August 19th at 2:00 PM ET BOSTON and LONDON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing novel Antibody Drug Conjugates ( [...]
Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
14/08/2025
– Live video webcast on Wednesday, August 20 th at 2:00 PM ET HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with [...]
NIH Contract Expands DLH’s Position as a Digital Transformation and Cybersecurity Leader
14/08/2025
Company to Continue Providing Information Technology Services for National Institutes of Health ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider [...]
À l’occasion de la Journée mondiale du don d’organes, le KFSHRC annonce la réalisation de 10 greffes de reins croisées en 48 heures
14/08/2025
RIYAD, Arabie saoudite, 14 août 2025 (GLOBE NEWSWIRE) -- Le King Faisal Specialist Hospital and Research Centre (KFSHRC) a réalisé avec succès 10 greffes de reins croisées en deux jours consécutifs, établissant ainsi le [...]
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
14/08/2025
Anaphylm launch funding of $75 million committed by RTW, subject to FDA approval of Anaphylm and other conditions Strategic financing will further strengthen the Company’s balance sheet in advance of potential [...]
Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation
14/08/2025
Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a webcast presentation [...]
Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update
14/08/2025
~ Achieved Second Quarter 2025 Total Net Revenues of $9.7 Million ~ ~ Double Digit New Accounts in the Second Quarter of 2025, Including Notable Quarter-Over-Quarter Growth in Both Large Community Practices and Academic [...]
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
14/08/2025
WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights
14/08/2025
– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 – – On track to dose first participant in Phase 1 clinical trial [...]
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
14/08/2025
Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic Reported positive topline data [...]
Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
14/08/2025
PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by [...]

Pages